| scholarly article | Q13442814 |
| P356 | DOI | 10.1179/1973947813Y.0000000078 |
| P698 | PubMed publication ID | 23906073 |
| P50 | author | Yolanda Sanz | Q60388687 |
| Tore Midtvedt | Q64052122 | ||
| Jacques Nicoli | Q56073291 | ||
| P2093 | author name string | Gianfranco Donelli | |
| Elisa Bertazzoni | |||
| P2860 | cites work | Probiotic supplementation in the first 6 months of life in at risk Asian infants - effects on eczema and atopic sensitization at the age of 1 year | Q57052721 |
| Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease | Q57124109 | ||
| Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial | Q57569167 | ||
| A Randomized Formula Controlled Trial of Bifidobacterium lactis and Streptococcus thermophilus for Prevention of Antibiotic-Associated Diarrhea in Infants | Q58227623 | ||
| Immunomodulating potential of supplementation with probiotics: a doseâ response study in healthy young adults | Q58816514 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Guidelines for the management of inflammatory bowel disease in adults | Q22242049 | ||
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| Lactobacillus GG in inducing and maintaining remission of Crohn's disease | Q24806098 | ||
| Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host | Q27335019 | ||
| Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial | Q28142345 | ||
| Saccharomyces boulardii in maintenance treatment of Crohn's disease | Q28144634 | ||
| Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial | Q28211907 | ||
| Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis | Q28212121 | ||
| Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial | Q28237525 | ||
| Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials | Q28242365 | ||
| Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo | Q47783890 | ||
| Meta-analysis: probiotics in antibiotic-associated diarrhoea | Q47858003 | ||
| Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study | Q48677169 | ||
| A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial | Q50622653 | ||
| Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. | Q50773084 | ||
| Probiotics and immunosenescence: cheese as a carrier. | Q51577012 | ||
| Probiotics during weaning reduce the incidence of eczema. | Q51760401 | ||
| Effect of oral application of a probiotic E. coli strain on the intestinal microflora of children of allergic mothers during the first year of life. | Q54439544 | ||
| Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. | Q54616148 | ||
| Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. | Q55036595 | ||
| Fecal microbiota transplantation: current status and future directions | Q28251016 | ||
| Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis | Q28266275 | ||
| Daily ingestion of fermented milk containing Lactobacillus casei DN114001 improves innate-defense capacity in healthy middle-aged people | Q28285488 | ||
| Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial | Q28287413 | ||
| Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats | Q28581568 | ||
| Saccharomyces boulardii'. A Review of an Innovative Biotherapeutic Agent | Q29013282 | ||
| Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children | Q29028534 | ||
| Probiotics promote gut health through stimulation of epithelial innate immunity | Q30437282 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). | Q33212468 | ||
| The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study | Q33433775 | ||
| A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. | Q33433931 | ||
| Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. | Q33435312 | ||
| Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial | Q33440895 | ||
| A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients | Q33590786 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study | Q33878836 | ||
| A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome | Q33955996 | ||
| Evidence-based guidelines for use of probiotics in preterm neonates | Q33977758 | ||
| A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome | Q34010853 | ||
| Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells | Q34013041 | ||
| Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials | Q34431156 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease | Q34517039 | ||
| Probiotics and Crohn's disease | Q34528530 | ||
| Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. | Q34547390 | ||
| A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease | Q34560319 | ||
| Probiotics improve bowel movements in hospitalized elderly patients--the PROAGE study | Q34627337 | ||
| Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial | Q34659239 | ||
| How host-microbial interactions shape the nutrient environment of the mammalian intestine | Q34675981 | ||
| Experimental effects of Saccharomyces boulardii on diarrheal pathogens | Q34688679 | ||
| Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota | Q34778107 | ||
| Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. | Q34825562 | ||
| Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk | Q34973957 | ||
| Probiotics: Considerations for Human Health | Q35118075 | ||
| Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study | Q35220787 | ||
| Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. | Q35233808 | ||
| Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial | Q35285379 | ||
| Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. | Q35542612 | ||
| Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens | Q35542616 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Aging of the human metaorganism: the microbial counterpart | Q35678151 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens | Q35890738 | ||
| Use of probiotics in children with acute diarrhea | Q36116450 | ||
| Probiotics: immunomodulation and evaluation of safety and efficacy | Q36402421 | ||
| Intestinal bacteria and ageing | Q36797288 | ||
| Meta-analysis of probiotics for the treatment of irritable bowel syndrome | Q37156630 | ||
| Lactobacillus fermentum ME-3 - an antimicrobial and antioxidative probiotic | Q37161945 | ||
| Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread | Q37365306 | ||
| Probiotic microbes: do they need to be alive to be beneficial? | Q37585644 | ||
| Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates | Q37733964 | ||
| Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants | Q37945420 | ||
| Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome | Q39348241 | ||
| A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Q39396709 | ||
| Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells | Q39536940 | ||
| The immunology of exceptional individuals: the lesson of centenarians. | Q40606515 | ||
| Enteral feeding of premature infants with Lactobacillus GG | Q41817204 | ||
| Management of acute diarrhoea with low osmolarity oral rehydration solutions and Lactobacillus strain GG. | Q41945166 | ||
| Probiotics and ileitis: could augmentation of TNF/NFκB activity be the answer? | Q42234301 | ||
| Effects of feeding premature infants with Lactobacillus GG on gut fermentation | Q42584461 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Use of VSL[sharp]3 in the treatment of rotavirus diarrhea in children: preliminary results | Q43744503 | ||
| Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis | Q43867015 | ||
| Disposition kinetics of Saccharomyces boulardii in man and rat. | Q44265947 | ||
| Enteral feeding of premature infants with Saccharomyces boulardii | Q44633338 | ||
| The probiotic effect of Saccharomyces boulardii in a pediatric age group | Q45051635 | ||
| Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis | Q45166043 | ||
| Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children | Q46069552 | ||
| Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
| Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the prevention of antibiotic-associated diarrhea in children: a randomized controlled pilot trial. | Q46430840 | ||
| Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial | Q47187980 | ||
| Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates | Q47370646 | ||
| Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial | Q47395591 | ||
| Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial | Q47407913 | ||
| P433 | issue | 4 | |
| P921 | main subject | probiotics | Q1816730 |
| P304 | page(s) | 193-212 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Journal of Chemotherapy | Q15754073 |
| P1476 | title | Probiotics and clinical effects: is the number what counts? | |
| P478 | volume | 25 |
| Q28069331 | A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis |
| Q64256348 | Effect of Cell Concentration on the Persistence in the Human Intestine of Four Probiotic Strains Administered through a Multispecies Formulation |
| Q36355121 | Effect of a probiotic beverage consumption (Enterococcus faecium CRL 183 and Bifidobacterium longum ATCC 15707) in rats with chemically induced colitis |
| Q92383670 | Effects of Lactobacillus acidophilus D2/CSL (CECT 4529) supplementation on healthy cat performance |
| Q37031303 | Experimental support for the effects of a probiotic/digestive enzyme supplement on serum cholesterol concentrations and the intestinal microbiome |
| Q28241661 | Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic |
| Q88337692 | High-intensity-exercise-induced intestinal damage is protected by fermented milk supplemented with whey protein, probiotic and pomegranate (Punica granatum L.). |
| Q97094546 | Molecular and in vitro assessment of some probiotic characteristics of amylolytic Lactobacillus plantarum strains from Bulgarian fermented products |
| Q35728214 | Non-alcoholic fatty liver disease, diet and gut microbiota. |
| Q41773158 | Oral administration of Lactobacillus paracasei NCC 2461 for the modulation of grass pollen allergic rhinitis: a randomized, placebo-controlled study during the pollen season |
| Q35278680 | Probiotics to counteract biofilm-associated infections: promising and conflicting data |
| Q39862587 | Supporting a healthy microbiome and patient outcomes with probiotics |
| Q35566214 | Survival of Lactobacillus casei strain Shirota in the intestines of healthy Chinese adults |
| Q35018033 | World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics |
Search more.